CELDOXOME PEGYLATED LIPOSOMAL

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania

Active ingredients

The drug CELDOXOME PEGYLATED LIPOSOMAL contains one active pharmaceutical ingredient (API):

1 Doxorubicin hydrochloride UNII 82F2G7BL4E - DOXORUBICIN HYDROCHLORIDE

Doxorubicin is a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. Read about Doxorubicin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CELDOXOME PEGYLATED LIPOSOMAL Concentrate for dispersion for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01DB01	Doxorubicin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DB Anthracyclines and related substances
Discover more medicines within L01DB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3040759, 3040760, 3040782, 3040793
Country: IT	Agenzia del Farmaco	Identifier(s): 050353010, 050353022, 050353034, 050353046
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095621, 1095622, 1095623, 1095624